Symrise presents clinical evidence for Symrise stock

Published on 10/22/2026 at 12:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Symrise presents clinical findings from 108 women on October 21, 2026. Symrise stock costs EUR 101.45, 0.45 percent above the Xetra close.

Clinical evidence and market context

Symrise presented results from 108 women on October 21, 2026.
Fiscal year 2025 revenue reached EUR 4,929 million, with a 21.9 percent EBITDA margin.
Symrise stock trades at EUR 101.45 at 12:20 p.m. CEST at Lang & Schwarz on October 22, 2026, 0.45 percent above the Xetra close of October 21, 2026.
Bernstein kept its EUR 99.00 target on October 20, 2026.

Flatlay mit Aktienzertifikat und Duftstoff-Utensilien, Symrise AG DE000SYM9999 — Symrise AG (DE000SYM9999) Flatlay kombiniert Aktienzertifikat, kleine Duftölfläschchen, getrocknete Vanilleschoten, Zitrusschalen und Lavendelzweige stilvoll arrangiert, Illustration mit AI erstellt.

Symrise (DE000SYM9999) presented clinical results from a 108-woman study on October 21, 2026, making health ingredients the latest company-specific catalyst. The company said the Acerowell study used a daily 600 milligram dose for 12 weeks, while more than 80 percent of participants reported improvements in skin luminosity, complexion and texture, according to Symrise. For the stock, the evidence adds a measurable product-development angle ahead of the next quarterly update.

Three recent signals shape the story

The chronology shows a company combining portfolio development with capital allocation. On October 19, 2026, Symrise disclosed that it had bought back 137,000 shares between October 12 and October 16, according to MarketScreener. On October 20, 2026, Bernstein analyst James Hooper kept a Neutral rating and a EUR 99.00 target, as reported by MarketScreener. The October 21 clinical release was the latest of the three events.

What does the evidence mean for growth?

The figures point to a broader health platform rather than a single ingredient launch. Symrise said the study involved 108 women, while a separate eight-week study covered 100 adults with occasional constipation. The company also presented postbiotic Rham271h at a daily dose of 10 billion TFU, giving the Care & Wellness division several quantified research points for customer discussions.

Dates investors can track

The next two company dates are both set for October 28, 2026: Symrise lists its third-quarter 2026 interim update and a virtual management roadshow on its investor-relations page. The same page reports fiscal year 2025 revenue of EUR 4,929 million, organic growth of 2.8 percent and an EBITDA margin of 21.9 percent, with the margin excluding the impairment of associate Swedencare, according to Symrise.

Stock price and valuation markers

Symrise stock was trading at EUR 101.45 at Lang & Schwarz on October 22, 2026 at 12:20 p.m. CEST, plus 0.45 percent versus the Xetra close of October 21, 2026 at EUR 101.00. The quote sits EUR 1.30 below the 52-week high of EUR 102.75, while market capitalization stood at EUR 13.9 billion on October 22, 2026. The further course of trading is shown by the continuously updated real-time quote of Symrise stock.